Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone734-369-2555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees27
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Zomedica Pharmaceuticals (CVE:ZOM) Frequently Asked Questions
What is Zomedica Pharmaceuticals' stock symbol?
Zomedica Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZOM."
How were Zomedica Pharmaceuticals' earnings last quarter?
Zomedica Pharmaceuticals Corp (CVE:ZOM) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.05. View Zomedica Pharmaceuticals' Earnings History.
When is Zomedica Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Zomedica Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zomedica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zomedica Pharmaceuticals.
Has Zomedica Pharmaceuticals been receiving favorable news coverage?
Media headlines about ZOM stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Zomedica Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Zomedica Pharmaceuticals.
Who are some of Zomedica Pharmaceuticals' key competitors?
Some companies that are related to Zomedica Pharmaceuticals include ICC Labs (ICC), Shield Therapeutics (STX), Althea Group (AGH), WeedMD (WMD), Auscann Group (AC8), Probiotec (PBP), Harvest One Cannabis (HVT), Delta 9 Cannabis (NINE), Invion (IVX), Depomed (ASRT), Biosyent (RX), ESSA Pharma (EPI), Eve & Co Inc (EVE), Science in Sport (SIS) and Pediapharm (MDP).
What other stocks do shareholders of Zomedica Pharmaceuticals own?
Who are Zomedica Pharmaceuticals' key executives?
Zomedica Pharmaceuticals' management team includes the folowing people:
- Mr. Gerald L. Solensky Jr., Chairman, Pres & CEO (Age 45)
- Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 52)
- Dr. Stephanie Morley D.V.M., DVM, COO & VP of Product Devel. (Age 44)
- Mr. Michael Schilk, VP of Sales
- Mr. David Eaton, VP of Marketing
How do I buy shares of Zomedica Pharmaceuticals?
Shares of ZOM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Zomedica Pharmaceuticals' stock price today?
One share of ZOM stock can currently be purchased for approximately C$0.56.
How big of a company is Zomedica Pharmaceuticals?
What is Zomedica Pharmaceuticals' official website?
How can I contact Zomedica Pharmaceuticals?
The company can be reached via phone at 734-369-2555.
MarketBeat Community Rating for Zomedica Pharmaceuticals (CVE ZOM)
MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
